Cargando…

NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome

Follicular lymphoma (FL) is a cancer of B-cells, representing the second most common type of non-Hodgkin lymphoma and typically diagnosed at advanced stage in older adults. In contrast to the wide range of available molecular genetic data, limited data relating the metabolomic features of follicular...

Descripción completa

Detalles Bibliográficos
Autores principales: Banoei, Mohammad Mehdi, Mahé, Etienne, Mansoor, Adnan, Stewart, Douglas, Winston, Brent W., Habibi, Hamid R., Shabani-Rad, Meer-Taher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117304/
https://www.ncbi.nlm.nih.gov/pubmed/35585165
http://dx.doi.org/10.1038/s41598-022-12445-5
_version_ 1784710304195674112
author Banoei, Mohammad Mehdi
Mahé, Etienne
Mansoor, Adnan
Stewart, Douglas
Winston, Brent W.
Habibi, Hamid R.
Shabani-Rad, Meer-Taher
author_facet Banoei, Mohammad Mehdi
Mahé, Etienne
Mansoor, Adnan
Stewart, Douglas
Winston, Brent W.
Habibi, Hamid R.
Shabani-Rad, Meer-Taher
author_sort Banoei, Mohammad Mehdi
collection PubMed
description Follicular lymphoma (FL) is a cancer of B-cells, representing the second most common type of non-Hodgkin lymphoma and typically diagnosed at advanced stage in older adults. In contrast to the wide range of available molecular genetic data, limited data relating the metabolomic features of follicular lymphoma are known. Metabolomics is a promising analytical approach employing metabolites (molecules < 1 kDa in size) as potential biomarkers in cancer research. In this pilot study, we performed proton nuclear magnetic resonance spectroscopy ((1)H-NMR) on 29 cases of FL and 11 control patient specimens. The resulting spectra were assessed by both unsupervised and supervised statistical methods. We report significantly discriminant metabolomic models of common metabolites distinguishing FL from control tissues. Within our FL case series, we also report discriminant metabolomic signatures predictive of progression-free survival.
format Online
Article
Text
id pubmed-9117304
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91173042022-05-20 NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome Banoei, Mohammad Mehdi Mahé, Etienne Mansoor, Adnan Stewart, Douglas Winston, Brent W. Habibi, Hamid R. Shabani-Rad, Meer-Taher Sci Rep Article Follicular lymphoma (FL) is a cancer of B-cells, representing the second most common type of non-Hodgkin lymphoma and typically diagnosed at advanced stage in older adults. In contrast to the wide range of available molecular genetic data, limited data relating the metabolomic features of follicular lymphoma are known. Metabolomics is a promising analytical approach employing metabolites (molecules < 1 kDa in size) as potential biomarkers in cancer research. In this pilot study, we performed proton nuclear magnetic resonance spectroscopy ((1)H-NMR) on 29 cases of FL and 11 control patient specimens. The resulting spectra were assessed by both unsupervised and supervised statistical methods. We report significantly discriminant metabolomic models of common metabolites distinguishing FL from control tissues. Within our FL case series, we also report discriminant metabolomic signatures predictive of progression-free survival. Nature Publishing Group UK 2022-05-18 /pmc/articles/PMC9117304/ /pubmed/35585165 http://dx.doi.org/10.1038/s41598-022-12445-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Banoei, Mohammad Mehdi
Mahé, Etienne
Mansoor, Adnan
Stewart, Douglas
Winston, Brent W.
Habibi, Hamid R.
Shabani-Rad, Meer-Taher
NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title_full NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title_fullStr NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title_full_unstemmed NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title_short NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
title_sort nmr-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117304/
https://www.ncbi.nlm.nih.gov/pubmed/35585165
http://dx.doi.org/10.1038/s41598-022-12445-5
work_keys_str_mv AT banoeimohammadmehdi nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT maheetienne nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT mansooradnan nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT stewartdouglas nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT winstonbrentw nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT habibihamidr nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome
AT shabaniradmeertaher nmrbasedmetabolomicprofilingcandifferentiatefollicularlymphomafrombenignlymphnodetissuesandmaybepredictiveofoutcome